Goldman cuts Carl Zeiss Meditec as ‘valuation disconnected from fundamentals’

Goldman Sachs downgraded Carl Zeiss Meditec to Sell from Neutral and cut its price target to €23 from €27, implying about 26% downside. It cited a challenged revenue outlook, IOL VBP 2.0, slower capital-equipment placements and increasing local competition; adjusted EBITDA estimates are +2% for FY26, -11% for FY27 and -6% for FY28. The shares are already down 21% year to date, but Goldman expects FY26 results, due 10 Dec, could prompt consensus estimates to reset lower.

Analysis

Fundamental read-through: The risk is a reinforcing demand loop, not simply slower equipment sales: centralized purchasing can defer placements, reduce utilization, and pressure procedure-linked demand, while local competition may limit pricing recovery. If that persists, cost actions may protect margins but cannot by themselves restore growth; savings are also execution- and timing-dependent. Potential beneficiaries are local suppliers able to win share, though the article provides no evidence to quantify that shift.

Catalysts and countercase: The December 10 results are the near-term test for whether estimates need another reset. Over 1–3 months, watch organic sales, adjusted operating profitability, placement trends, and management’s quantified savings and demand commentary. Over 6–18 months, the key question is whether procedure volumes and equipment utilization stabilize. The parent’s announced investment may cushion selling pressure, so its support should not be assumed to vanish immediately. Conversely, the existing share-price decline and a genuine cost-control shift leave room for a relief rally if results merely meet expectations. This is a bearish setup, but not a clean short without confirmation.

Key Decisions for Investors

• Maintain an underweight bias in AFX; consider a small tactical short only on a failed post-downgrade rebound or after results confirm weaker demand. Avoid sizing as though the analyst downgrade alone guarantees further downside.
• Use the December 10 report as the principal decision point. Add to the short only if management lowers or qualifies the revenue outlook, placement/utilization indicators weaken, or savings are delayed; cover or reassess if demand stabilizes and cost benefits are evidenced in reported results.
• For a market-neutral expression, pair a short AFX position with long diversified European medtech exposure rather than betting on broad sector weakness. Recheck peer and instrument selection before execution; no peer valuation or hedge ratio is established by the supplied information.
• Falsifiers: sustained improvement in organic sales and equipment utilization, credible delivery of restructuring savings, or continued parent share purchases that materially support the stock. Verify actual purchase activity, segment-level trends, and consensus revisions before increasing exposure.